Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Ginekologia Polska
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 86, No 7 (2015)
ARTICLES
View PDF Download PDF file
Get Citation

Survivin in ovary tumors

Danuta Plewka, Beata Jakubiec-Bartnik, Michał Morek, Edyta Bogunia, Marek Bienioszek, Hubert Wolski, Daniel Kotrych, Karolina Dziekan, Agnieszka Seremak-Mrozikiewicz, Andrzej Plewka
DOI: 10.17772/gp/57855
·
Ginekol Pol 2015;86(7).

open access

Vol 86, No 7 (2015)
ARTICLES

Abstract

Objectives Introduction: Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which are selectively overexpressed in human neoplasms, and its expression has been shown to be connected with cell proliferation. We analyzed survivin expression in ovarian epithelial neoplasms to evaluate its role in the development of ovarian tumors. Material and methods: Immunohistochemistry assays were conducted in 137 cases (48 ovarian carcinoma, 43 borderline ovarian carcinoma, 46 benign ovarian tumor, and 20 samples of normal ovarian tissue of ovarian epithelial neoplasms. Histological types included serous (n=68) and mucinous (n=69) tumors. All tumors were reviewed histopathologically and classified according to the WHO criteria. Results: Survivin expression in the group of serous neoplasms was detected in 24.0% (6 of 25) of benign cases, in 60.0% (12 of 20) of borderline tumors, and 91.0% (24 of 47) of ovarian carcinomas. In the group of mucinous tumors, survivin expression was found in 33.5% (7 of 21) of benign cases, 43.5% (10 of 23) of borderline tumors, and 80.0% (20 of 25) of malignant tumors. Conclusions: Our results demonstrate that survivin overexpression may play a crucial role in the development of epithelial ovarian neoplasms and be an important prognostic factor for the influence of survivin expression on epithelial ovarian cancers.

Abstract

Objectives Introduction: Survivin is a member of the inhibitor of apoptosis protein (IAP) family, which are selectively overexpressed in human neoplasms, and its expression has been shown to be connected with cell proliferation. We analyzed survivin expression in ovarian epithelial neoplasms to evaluate its role in the development of ovarian tumors. Material and methods: Immunohistochemistry assays were conducted in 137 cases (48 ovarian carcinoma, 43 borderline ovarian carcinoma, 46 benign ovarian tumor, and 20 samples of normal ovarian tissue of ovarian epithelial neoplasms. Histological types included serous (n=68) and mucinous (n=69) tumors. All tumors were reviewed histopathologically and classified according to the WHO criteria. Results: Survivin expression in the group of serous neoplasms was detected in 24.0% (6 of 25) of benign cases, in 60.0% (12 of 20) of borderline tumors, and 91.0% (24 of 47) of ovarian carcinomas. In the group of mucinous tumors, survivin expression was found in 33.5% (7 of 21) of benign cases, 43.5% (10 of 23) of borderline tumors, and 80.0% (20 of 25) of malignant tumors. Conclusions: Our results demonstrate that survivin overexpression may play a crucial role in the development of epithelial ovarian neoplasms and be an important prognostic factor for the influence of survivin expression on epithelial ovarian cancers.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

ovarian cancer subtypes, IHC, survivin

About this article
Title

Survivin in ovary tumors

Journal

Ginekologia Polska

Issue

Vol 86, No 7 (2015)

Page views

1145

Article views/downloads

1022

DOI

10.17772/gp/57855

Bibliographic record

Ginekol Pol 2015;86(7).

Keywords

ovarian cancer subtypes
IHC
survivin

Authors

Danuta Plewka
Beata Jakubiec-Bartnik
Michał Morek
Edyta Bogunia
Marek Bienioszek
Hubert Wolski
Daniel Kotrych
Karolina Dziekan
Agnieszka Seremak-Mrozikiewicz
Andrzej Plewka

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl